10 can't-miss Houston business and innovation events in July

where to be

Check out these workshops, networking events, pitch events, and other goings on in Houston and online this month. Photo via Getty Images

This month, Houstonians have yet another good batch of online innovation events — from Zoom panels to virtual conferences — and you and your tech network need to know about them.

Here's a roundup of virtual events not to miss this month — like demo days, workshops, conventions, and more.

Note: This post might be updated to add more events.

July 7 — gBETA Summer 2021 Pitch Night

Pitch Night is a celebration of gBETA Houston's latest cohort. Pitch Night is an exclusive reception during which participating companies have the opportunity to pitch to an audience of entrepreneurs, mentors, investors and community members.

The event is on Wednesday, July 7, at 5:30 pm. It's free and happening at The Cannon (1334 Brittmoore Rd) and online. Click here to register.

July 8 — Esperson Coworking Powered by The Cannon Soft Opening

The Cannon is operating new coworking space in Downtown Houston in the Esperson Building. Celebrate the soft opening with networking in the new space.

The event is on Thursday, July 8, at 3 pm. It's free and happening at the Esperson Building (808 Travis St.). Click here to register.

July 14 — People & Culture - Talent strategy is core to any business, so how do you make sure an external hire will succeed?

Did you know that more than half of external new hires fail within their first 18 months. The reason behind it: the expectations and competencies are misaligned with the recruitment process, which then are also not connected with onboarding and performance KPIs after the process is completed. The event will explore the process from end to end, diving into the main issues that lead to mistakes in executive searches. After you learn our DIY model, you can apply to external hires in levels.

The event is on Wednesday, July 14, at 11 am. It's free and happening online. Click here to register.

July 14-15 — Innovation & Entrepreneurship Summit

The Society of Petroleum Engineers' 2021 program addresses how firms are navigating the current economics of the energy industry, alternative energy partnerships, carbon innovation, resiliency in innovation, and concludes with our interactive and competitive Shark-Tank event, highlighting delivery of the next entrepreneurial solutions.

The Innovation and Entrepreneurship Summit is your premier opportunity to build connections and to pursue new solutions within the Energy industry.

The event is on Wednesday, July 14, through Thursday, July 15. Tickets begin at $80. The conference will be held at Norris Conference Center, CityCentre (816 Town & Country Blvd., Suite 210). Click here to register.

July 15 — Solving Startup Challenges at the Corvaverse

Do you have a specific startup challenge or problem you can't seem to solve? Join The Cannon and Corva for lunch and breakout sessions with industry leaders and advisors who will be sharing tips on solutions. Additionally, you will hear from Corva's CEO, Ryan Dawson, who will share his journey. It's going to be an eventful, collaborative and fun time that you don't want to miss.

The event is on Thursday, July 15, at noon. It's free and happening at The Cannon West Houston (1334 Brittmoore Rd.). Click here to register.

July 17-18 — Comicpalooza 

The greatest pop-culture festival returns with celebrities, shopping, and pop culture activities that will unite, inspire, and entertain.

The event is on Saturday, July 17, through Sunday, July 18. Passes start at $54 and the festival is happening at George R. Brown Convention Center (1001 Avenida De Las Americas). Click here to register.

July 21 —  How to Invest in Space

Join Houston Angel Network for a discussion with key thought leaders in the public and private space industry about how to invest in space.

The event is on Wednesday, July 21, at 11:30 am. It's $25 to attend and happening online. Click here to register.

July 23 — HAN Summer Social

Join the Houston Angel Network and Houston Exponential for investor and founder networking over drinks.

The event is on Friday, July 23, at 5 pm. It's free to HAN members and $25 for everyone else. It's happening at Buffalo Bayou Brewing Co. (2101 Summer St.). Click here to register.

July 28 — Understanding Financial Statements

Frost Bank's VP of Commercial Banking will help entrepreneurs learn how to analyze their cash flow to strengthen their business strategy.

The event is on Wednesday, July 28, at 11:30 am. It's free and happening online. Click here to register.

July 28 — Houston Startup Showcase

Hear a select group of local tech startups pitch their company, share their current status, and tell us where they're headed next at this monthly event hosted by The Ion.

The event is on Wednesday, July 28, at 6 pm. It's free and happening online. Click here to register.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings